Nitrogen Other Than As Nitro Or Nitroso Nonionically Bonded Patents (Class 514/561)
  • Patent number: 10660887
    Abstract: Compositions and methods for the treatment of depression and psychoses in humans are disclosed. More particularly, the invention is directed to formulations containing antipsychotic and/or antidepressant medications and also containing an NMDAR antagonist. The present Invention Is also directed to methods tor the treatment of humans suffering from depression and other psychoses, including, schizophrenia, by administration of the inventive compositions in antidepressant and/or antipsychotic effective amounts.
    Type: Grant
    Filed: July 16, 2017
    Date of Patent: May 26, 2020
    Assignee: GLYTECH, LLC
    Inventor: Daniel C. Javitt
  • Patent number: 10654794
    Abstract: Disclosed are a fused tricyclic ?-amino acid derivative and a medical use thereof, in particular, the present invention relates to a fused cyclic ?-amino acid derivative as shown in general formula (I), or a stereoisomer, solvate, metabolite, prodrug, pharmaceutically acceptable salt or eutectic thereof, a pharmaceutical composition containing same, and the use of a compound or the composition in the field of analgesia, wherein the definitions of each substituent in general formula (I) are the same as the definitions in the description.
    Type: Grant
    Filed: September 12, 2017
    Date of Patent: May 19, 2020
    Assignee: SICHUAN HAISO PHARMACEUTICAL CO., LTD.
    Inventors: Yao Li, Zongjun Shi, Bo Xu
  • Patent number: 10646435
    Abstract: The present invention provides pasty or liquid compositions for applications on mucous membranes of cavities easily reached by hand, having a bio-adhesive prolonged effect or release. The composition includes a polysaccharide matrix agent selected from the group constituting of lambda carrageenan and iota carrageenan. The matrix allows the in situ formation of a matrix film with a reinforced bio-adhesive capacity due to complexation reactions between the polysaccharide matrix agent and the components of the local secretions of the mucous membranes. The compositions can also include a lecithin compound as a reinforcing agent of the intrinsic bio-adhesive properties of the polysaccharide matrix agent. The composition can further include at least one of (a) a hydration medium for the polysaccharide matrix agent, (b) a lecithin co-solvent allowing the dispersion of the micellar lecithin solution in the hydration medium, (c) an additive or additives, and (d) at least one active ingredient.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: May 12, 2020
    Assignee: CARE & PHARMA PERSPECTIVES SA
    Inventor: Laurence Paris
  • Patent number: 10596136
    Abstract: This disclosure provides methods of using compositions comprising amino acid entities to reduce fat infiltration in muscle, particularly under conditions of muscle atrophy. The disclosure also provides methods for enhancing muscle function by reducing fat infiltration in the muscle comprising administering an effective amount of the compositions to a subject in need thereof.
    Type: Grant
    Filed: June 19, 2019
    Date of Patent: March 24, 2020
    Assignee: AXCELLA HEALTH INC.
    Inventors: Manu Chakravarthy, William Comb, Michael Hamill, Tony Tramontin
  • Patent number: 10588882
    Abstract: The invention features a pharmaceutical suspension containing drug particles, a drug delivery device anchored in the mouth for continuously administering the pharmaceutical suspension, and methods of their use.
    Type: Grant
    Filed: June 10, 2019
    Date of Patent: March 17, 2020
    Assignee: SynAgile Corporation
    Inventors: Adam Heller, John Spiridigliozzi
  • Patent number: 10583138
    Abstract: This application relates to combination compositions for use in treatment of depression, and which can alleviate the anxiogenic side effects of certain antidepressant and antipsychotic medications. Methods for treatment of depression and medicament side effects, particular anxiety, akathisia, and associated suicidality are also described herein.
    Type: Grant
    Filed: May 24, 2018
    Date of Patent: March 10, 2020
    Assignee: GLYTECH, LLC
    Inventor: Daniel C. Javitt
  • Patent number: 10485776
    Abstract: A medicament to be applied as an external preparation for therapeutic treatment of a local symptom of a neuropathic disease, which contains gabapentin or pregabalin in the form of an aqueous solution.
    Type: Grant
    Filed: May 23, 2018
    Date of Patent: November 26, 2019
    Assignee: KEMPHYS LTD.
    Inventors: Koichi Shudo, Kiyoshi Sugiyama
  • Patent number: 10426792
    Abstract: Compositions and supplement formulations comprise at least one of Carnitine, Taurine, or derivative forms thereof. In one aspect, the composition or a supplement formulation comprises at least one Amino Acid constituent selected from the group consisting of Carnitine, Taurine, and derivative forms thereof; and at least one Nitrate constituent. In another aspect, the composition or a supplement formulation comprises a Nitrate of a compound selected from the group consisting of Carnitine, Taurine, and derivative forms thereof, wherein the Nitrate is a salt of Nitrate or a mixed salt of Nitrate. The compositions and supplement formulations may be formulated for improving athletic performance, increasing the bioabsorption of Carnitine, Taurine, or derivative forms thereof, or for increasing the vasodilative characteristics.
    Type: Grant
    Filed: February 13, 2015
    Date of Patent: October 1, 2019
    Assignee: ThermoLife International, LLC
    Inventors: Ronald Kramer, Alexander Nikolaidis
  • Patent number: 10420783
    Abstract: The present invention relates to a foodstuff comprising feather hydrolysate for use in improving performance during exercise and/or improving recovery after exercise in a dog. It also relates to a method of improving the performance in a dog during exercise and/or improving recovery after exercise, the method comprising administering to a dog a foodstuff which comprises feather hydrolysate.
    Type: Grant
    Filed: June 20, 2014
    Date of Patent: September 24, 2019
    Assignee: Mars, Incorporated
    Inventors: Alexandre Feugier, Delphine Clero
  • Patent number: 10363246
    Abstract: Use of allosteric modulators and/or gaboxadol for the treatment of epileptic disorders in a subject in need thereof.
    Type: Grant
    Filed: March 18, 2019
    Date of Patent: July 30, 2019
    Assignee: Ovid Therapeutics Inc.
    Inventor: Matthew During
  • Patent number: 10351608
    Abstract: The present invention provides a method for treating a human patient with a pathology by administering to the subject an effective amount of an agent selected from the group of: native full-length CCN3 proteins; analog CCN3 full-length proteins with native cysteine residues substituted by a replacement amino acid; CCNp native peptide fragments having from about 12 to about 20 amino acids; analog CCNp peptide fragments with native cysteine residues substituted with a replacement amino acid; and combinations thereof.
    Type: Grant
    Filed: August 7, 2015
    Date of Patent: July 16, 2019
    Assignee: Rosalind Franklin University of Medicine and Science
    Inventor: Bruce L. Riser
  • Patent number: 10328041
    Abstract: The present disclosure provides co-crystals of a substituted glycine compound and a co-former compound of Formula (I): compositions comprising such, and uses thereof in treating and/or reducing the risk for a neuropsychiatric disorder (e.g., schizophrenia, psychotic disorders, depressive disorders, suicidal ideation and/or behavior, obsessive compulsive disorder or Alzheimer's disease). Also provided herein are methods for preparing the co-crystals.
    Type: Grant
    Filed: January 9, 2018
    Date of Patent: June 25, 2019
    Assignee: SyneuRx International (Taiwan) Corp.
    Inventors: Guochuan Emil Tsai, Ching-Cheng Wang, Tien-Lan Hsieh
  • Patent number: 10328042
    Abstract: The present disclosure provides co-crystals of a substituted glycine compound and a co-former compound of Formula (I): compositions comprising such, and uses thereof in treating and/or reducing the risk for a neuropsychiatric disorder (e.g., schizophrenia, psychotic disorders, depressive disorders, suicidal ideation and/or behavior, obsessive compulsive disorder or Alzheimer's disease). Also provided herein are methods for preparing the co-crystals.
    Type: Grant
    Filed: April 3, 2018
    Date of Patent: June 25, 2019
    Assignee: SyneuRx International (Taiwan) Corp.
    Inventors: Guochuan Emil Tsai, Ching-Cheng Wang, Tien-Lan Hsieh
  • Patent number: 10328044
    Abstract: The invention features a pharmaceutical suspension containing drug particles, a drug delivery device anchored in the mouth for continuously administering the pharmaceutical suspension, and methods of their use.
    Type: Grant
    Filed: December 14, 2018
    Date of Patent: June 25, 2019
    Assignee: SynAgile Corporation
    Inventor: Adam Heller
  • Patent number: 10307387
    Abstract: D-serine is used to treat a neurological disorder, such as epilepsy, that cases seizures. A composition comprising D-serine is artificially administered to a patient in an effective amount by selectively contacting a region of the patient's brain with the composition. The region of the brain selectively contacted with the composition has cells expressing GluN3 subunit-containing triheteromeric NMDARs.
    Type: Grant
    Filed: December 7, 2017
    Date of Patent: June 4, 2019
    Assignee: Florida State University Research Foundation, Inc.
    Inventor: Sanjay Kumar
  • Patent number: 10306909
    Abstract: The present invention is based on the finding that free amino acids can both negatively or positively influence overall taste of free amino acid-based enteral nutritional compositions, and the amino acids can thus be categorized. A striking balance of both categories of amino acids to arrive at amino acid-based nutritional composition with improved taste, yet not compromising the (regulatory) dietary restrictions on essential amino acids and conditionally essential amino acids.
    Type: Grant
    Filed: June 30, 2015
    Date of Patent: June 4, 2019
    Assignee: N.V. NUTRICIA
    Inventors: Jonathan Rason, Carole Springett
  • Patent number: 10300033
    Abstract: The invention features a pharmaceutical suspension containing drug particles, a drug delivery device anchored in the mouth for continuously administering the pharmaceutical suspension, and methods of their use.
    Type: Grant
    Filed: February 2, 2018
    Date of Patent: May 28, 2019
    Assignee: SynAgile Corporation
    Inventor: Adam Heller
  • Patent number: 10265278
    Abstract: The present invention provides a pharmaceutical composition for oral administration comprising a D-amino acid combined with an antioxidant selected from the group consisting of vitamin E, vitamin C, a glutathione or a precursor thereof.
    Type: Grant
    Filed: February 20, 2017
    Date of Patent: April 23, 2019
    Inventor: Daniel Javitt
  • Patent number: 10255497
    Abstract: The invention relates to a method and to a device for authenticating and/or identifying persons, objects, or service systems. In said method, a material, a construction, a substance, or a composition, or an image thereof, either changes itself or is actively changed, by means of a physical, chemical, or mechanical influence or feature, such that the resulting structure or feature is unforeseeable. If an image of said material, of the construction, of the substance, or the composition recorded at a later time is compared with the image stored in a storage means, the person and/or the object and/or the medium and/or service system is positively authenticated if the material, the construction, the substance, or the composition has at least partially changed between the two times in comparison with the image stored in the storage means.
    Type: Grant
    Filed: March 18, 2015
    Date of Patent: April 9, 2019
    Inventor: Friedrich Kisters
  • Patent number: 10241093
    Abstract: The present invention provides markers and methods for determining whether a subject, particularly a human subject, has or is at risk of developing, a disease such as cardiovascular disease, diabetes mellitus, insulin resistance, metabolic syndrome, NAFLD (Nonalcoholic Fatty Liver Disease) or NASH (Nonalcoholic Steatohepatitis) (e.g., within the ensuing year, two years, and/or three years). The present application also relates to the use of such markers and methods for monitoring the status of such diseases in a subject or the effects of therapeutic agents on subjects with such diseases.
    Type: Grant
    Filed: November 28, 2011
    Date of Patent: March 26, 2019
    Assignee: The Cleveland Clinic Foundation
    Inventors: Stanley L. Hazen, Zeneng Wang, Bruce S. Levison
  • Patent number: 10188635
    Abstract: Methods of treating tinnitus with gaboxadol or a pharmaceutically acceptable salt thereof are provided. The methods provide therapeutic compositions that may be used to improve one or more symptoms of tinnitus.
    Type: Grant
    Filed: August 7, 2018
    Date of Patent: January 29, 2019
    Assignee: OVID THERAPEUTICS INC.
    Inventor: Matthew During
  • Patent number: 10136669
    Abstract: A nutritional composition is provided which has an effective prophylactic and/or improving effect for various symptoms of muscle mass decrease, decreased basal metabolism, low body temperature, suppression of obesity, suppression of visceral fat accumulation, hyperglycemia, hyperlipidemia and the like in elderly people. The nutritional composition can include n-3 fatty acid and one or more of free lysine, dipeptides containing lysine, and lysine salts, wherein the content of free lysine, dipeptides containing lysine, and/or lysine salts is 0.1 g-10.0 g per 100 kcal of the composition, and the content of the total amount of n-3 fatty acid is 0.17 g-5.00 g per 100 kcal of the composition.
    Type: Grant
    Filed: August 25, 2016
    Date of Patent: November 27, 2018
    Assignee: AJINOMOTO CO., INC.
    Inventors: Tomoyuki Mine, Naoki Hayashi, Itaru Kon, Kazunori Saima
  • Patent number: 10137288
    Abstract: This invention relates to an ingestible drug delivery device configured for wireless communication with other ingestible drug delivery devices.
    Type: Grant
    Filed: November 27, 2017
    Date of Patent: November 27, 2018
    Assignee: Pop Test Abuse Deterrent Technology, LLC
    Inventors: Randice Lisa Altschul, Neil David Theise, Razvan Andrei Ene, Myron Rapkin, Rebecca O'Brien
  • Patent number: 10098856
    Abstract: A combination of dosage units for alleviating respiratory ailments and a method of alleviating respiratory ailments which uses this combination of dosage units. The dosage units comprise one or more first dosage units comprising pseudoephedrine and/or a pharmaceutically acceptable salt thereof and one or more second dosage units comprising phenylephrine and/or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: June 2, 2016
    Date of Patent: October 16, 2018
    Assignee: Sovereign Pharmaceuticals, LLC
    Inventors: Suresh Dixit, Juan Carlos Menendez, Ralph Brown
  • Patent number: 10076573
    Abstract: Biodegradable polyphosphazene polymers containing pyrrolidone side groups, and the biomedical use of such polyphosphazene polymers are disclosed.
    Type: Grant
    Filed: November 7, 2014
    Date of Patent: September 18, 2018
    Assignee: Innovo Biopolymers, LLC
    Inventors: Alexander Andrianov, Alexander Marin
  • Patent number: 10071083
    Abstract: Methods of treating tinnitus with gaboxadol or a pharmaceutically acceptable salt thereof are provided. Also provided are therapeutic compositions that may be used to improve one or more symptoms of tinnitus. Methods of treating acute sensorineural hearing loss or Meniere's disease with gaboxadol or a pharmaceutically acceptable salt thereof are provided. Also provided are therapeutic compositions that may be used to improve one or more symptoms of acute sensorineural hearing loss or Meniere's disease.
    Type: Grant
    Filed: January 17, 2018
    Date of Patent: September 11, 2018
    Assignee: OVID THERAPEUTICS INC
    Inventor: Matthew During
  • Patent number: 10052296
    Abstract: Formulations, methods of manufacturing, methods of stabilizing, kits, and uses as medicament are provided, for example for the treatment of pain. The formulations can comprise gabapentin optionally combined with at least one non-opioid pain drug in an aqueous carrier. The pharmaceutical formulation can have a pH of about 2.0 to about 10.0. The at least one non-opioid pain drug can be acetaminophen. The components can be included in any amount suitable for purposes of obtaining properties desirable for an injectable infusion, for example an intravenous infusion.
    Type: Grant
    Filed: April 7, 2017
    Date of Patent: August 21, 2018
    Assignee: NEVAKAR INC.
    Inventors: Varun Khurana, Vivek Yadav, Jack Martin Lipman, Tao Zhang, Iouri V. Ilitchev, Tushar Hingorani, Kumaresh Soppimath, Navneet Puri
  • Patent number: 10022446
    Abstract: A pH-responsive hybrid hydrogel, namely poly(Methacrylic acid-grafted-Ethylene Glycol) P(MAA-g-EG) cross-linked with Styrene-Butadiene-Styrene (SBS) polymer and photopolymerized by visible light. The resulting polymer turned out to have better integrities, high swelling ratios, pH-responsive and biocompatible character. Also the visible-light-induced synthesis of these pH-responsive composite wherein eosin Y is used as photoinitiator and triethanolamine is used as a co-initiator is also disclosed in the invention.
    Type: Grant
    Filed: August 22, 2014
    Date of Patent: July 17, 2018
    Assignee: KOç ÜNIVERSITESI
    Inventors: Seda Kizilel, Ozlem Cevik
  • Patent number: 10018591
    Abstract: A method for determining the levels of biomarkers, specifically, advanced glycation end products (AGEs) and oxidation products (Ops) in a biological sample such as a plasma ultrafiltrate, is used to determine a patient's risk and/or rate of developing diabetes related nephropathy. The preferred biomarkers to measure include N?-(1-carboxyethyl-lysine (CEL), methylglyoxyl-derived hydroimidazolone (MGHI) and N?-carboxymethyllysine (CML). Also provided herein is a method of diabetic care which includes determining a diabetic patient's risk of developing diabetes related kidney disease and adjusting the patient's treatment regimen to include in addition to glucose lowering agents, additional treatments such as medications that modify the renin-angiotensin system, or specialized diets with low levels of AGEs or oxidative products.
    Type: Grant
    Filed: June 10, 2013
    Date of Patent: July 10, 2018
    Assignee: PREVENTAGE HEALTHCARE, LLC
    Inventor: Paul J. Beisswenger
  • Patent number: 10010703
    Abstract: This invention relates to an ingestible drug delivery device configured for wireless communication with other ingestible drug delivery devices.
    Type: Grant
    Filed: November 27, 2017
    Date of Patent: July 3, 2018
    Assignee: Pop Test Abuse Deterrent Technology, LLC
    Inventors: Randice Lisa Altschul, Neil David Theise, Razvan Andrei Ene, Myron Rapkin, Rebecca O'Brien
  • Patent number: 10004710
    Abstract: A medicament to be applied as an external preparation for therapeutic treatment of a local symptom of a neuropathic disease, which contains gabapentin or pregabalin in the form of an aqueous solution.
    Type: Grant
    Filed: September 4, 2013
    Date of Patent: June 26, 2018
    Assignee: KEMPHYS LTD.
    Inventors: Koichi Shudo, Kiyoshi Sugiyama
  • Patent number: 9961932
    Abstract: The invention pertains to the use of a composition comprising per serving between 50-300 kcal; between 10 g and 35 g proteinaceous matter; and at least 2.5 microgram vitamin D, for the manufacture of a nutritional product for (a) the treatment or prevention of muscle mass decrease, (b) stimulation of muscle mass increase; or (d) stimulating muscle mass preservation, in obese or overweight adults of at least 40 years of age participating in a weight loss program. The inventors surprisingly found that nutritional supplementation with a low-caloric composition rich in protein, particularly whey protein and leucine, compared to an iso-caloric control supplement without protein, synergistically leads to preservation of muscle mass during a weight loss program involving a hypocaloric diet and a resistance exercise program in overweight/obese older adult.
    Type: Grant
    Filed: June 10, 2013
    Date of Patent: May 8, 2018
    Assignee: N.V. Nutricia
    Inventors: Peter Johan Marie Weijs, Johan De Vogel, George Verlaan, Marion Jourdan
  • Patent number: 9937138
    Abstract: The present invention provides an agent for promoting graft survival which can suppress rejection without use of existing immunosuppressants, an organ preservation solution capable of maintaining the freshness of an organ excised from a donor, and the like. An agent for promoting graft survival or an organ preservation solution is prepared, which comprises 5-aminolevulinic acid (ALA) or a derivative thereof, or a salt of ALA or the derivative and an iron compound as active ingredients. Preferable examples of the ALAs can include ALA and various esters such as methyl ester, ethyl ester, propyl ester, butyl ester, and pentyl ester of ALA, and their hydrochlorides, phosphates, and sulfates. Preferable examples of the iron compound can include sodium ferrous citrate.
    Type: Grant
    Filed: March 9, 2016
    Date of Patent: April 10, 2018
    Assignees: National Center for Child Health and Development, SBI Pharmaceuticals Co., Ltd.
    Inventors: Ko Rii, Kiwamu Takahashi, Naomi Haga, Fuminori Abe, Tohru Tanaka, Motowo Nakajima, Hidenori Ito
  • Patent number: 9926515
    Abstract: The invention is related to a contact lens care solution comprising a buffer solution, a chelating agent, a surfactant and a wetting agent, wherein the wetting agent comprises 100 parts by weight of glycerol, 0.5 to 40 parts by weight of vinylacetamide-containing polymer and 5 to 40 parts by weight of alginic acid.
    Type: Grant
    Filed: January 3, 2017
    Date of Patent: March 27, 2018
    Assignee: BENQ MATERIALS CORPORATION
    Inventors: Fan-Dan Jan, Bo-Ching Lin, Min-Chun Chung
  • Patent number: 9925159
    Abstract: D-serine is used to treat a neurological disorder, such as epilepsy, that cases seizures. A composition comprising D-serine is artificially administered to a patient in an effective amount by selectively contacting a region of the patient's brain with the composition. The region of the brain selectively contacted with the composition has cells expressing GluN3 subunit-containing triheteromeric NMDARs.
    Type: Grant
    Filed: May 15, 2015
    Date of Patent: March 27, 2018
    Assignee: The Florida State University Research Foundation, Inc.
    Inventor: Sanjay Kumar
  • Patent number: 9913808
    Abstract: The present invention relates to an injectable pharmaceutical formulation for the alleviation or reduction of joint irritation or for the reduction of worsening of existing joint inflammation, formulated for intra-articular injection comprising an active polyol ingredient, which polyol active ingredient is xylitol. Use of the intra-articular injectable formulations for the treatment of joint diseases or conditions including arthritis is described.
    Type: Grant
    Filed: June 15, 2011
    Date of Patent: March 13, 2018
    Inventor: David Segal
  • Patent number: 9901561
    Abstract: The invention features a pharmaceutical suspension containing drug particles, a drug delivery device anchored in the mouth for continuously administering the pharmaceutical suspension, and methods of their use.
    Type: Grant
    Filed: March 2, 2017
    Date of Patent: February 27, 2018
    Assignee: SynAgile Corporation
    Inventors: Adam Heller, Ephraim Heller, Karl Göran Westerberg, John Spiridigliozzi
  • Patent number: 9877942
    Abstract: The present disclosure provides co-crystals of a substituted glycine compound and a co-former compound of Formula (I): compositions comprising such, and uses thereof in treating and/or reducing the risk for a neuropsychiatric disorder (e.g., schizophrenia, psychotic disorders, depressive disorders, suicidal ideation and/or behavior, obsessive compulsive disorder or Alzheimer's disease). Also provided herein are methods for preparing the co-crystals.
    Type: Grant
    Filed: February 13, 2017
    Date of Patent: January 30, 2018
    Assignee: SyneuRx International (Taiwan) Corp.
    Inventors: Guochuan Emil Tsai, Ching-Cheng Wang, Tien-Lan Hsieh
  • Patent number: 9878139
    Abstract: This invention relates to an ingestible drug delivery device configured for wireless communication with other ingestible drug delivery devices.
    Type: Grant
    Filed: April 21, 2017
    Date of Patent: January 30, 2018
    Assignee: Pop Test Abuse Deterrent Technology, LLC
    Inventors: Randice Lisa Altschul, Neil David Theise, Razvan Andrei Ene, Myron Rapkin, Rebecca O'Brien
  • Patent number: 9878138
    Abstract: This invention relates to an ingestible drug delivery device configured for wireless communication with other ingestible drug delivery devices.
    Type: Grant
    Filed: May 4, 2015
    Date of Patent: January 30, 2018
    Assignee: Pop Test Abuse Deterrent Technology LLC
    Inventors: Randice Lisa Altschul, Neil David Theise, Razvan Andrei Ene, Myron Rapkin, Rebecca O'Brien
  • Patent number: 9833403
    Abstract: The invention described herein is related to the preparation and usage of nanoemulsions and nanoparticles which containing biological active ingredients including cosmetic, medical and pharmaceutical active ingredients to pass skin barriers and promote cell growth with evident clinical effects. Also, the present invention contains a cosmetic formulation that can be used for skin rejuvenation, wrinkle removal, scar treatment and wounds healing.
    Type: Grant
    Filed: December 31, 2013
    Date of Patent: December 5, 2017
    Inventors: Huiwen Liu, Boke Zhang
  • Patent number: 9770421
    Abstract: The present invention relates to the use of a 1,4-benzoquinone derived compound for the treatment of a disease or condition that is associated with peroxisome proliferator activated receptor (PPAR) activity in a mammal.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: September 26, 2017
    Assignee: INDANIO BIOSCIENCE INC.
    Inventors: Henry Krause, Jens Tiefenbach
  • Patent number: 9763936
    Abstract: The invention relates to the use of Flibanserin for the treatment or prevention of urinary incontinence and related diseases. In a further embodiment, the instant invention is directed to pharmaceutical combinations comprising flibanserin as one active ingredient in combination with at least one additional active ingredient for the treatment or prevention of urinary incontinence and related diseases.
    Type: Grant
    Filed: July 27, 2015
    Date of Patent: September 19, 2017
    Assignee: Sprout Pharmaceuticals, Inc.
    Inventors: Ramiro Castro, Angelo Ceci
  • Patent number: 9693982
    Abstract: The present invention is directed to a composition for ameliorating hypoalbuminemia containing a branched-chain amino acid(s) as an active ingredient(s), wherein the composition contains leucine and/or isoleucine as the active ingredient(s) and does not contain valine. As the above branched-chain amino acid(s), leucine and isoleucine are preferably contained. The mass ratio of leucine to isoleucine described above is preferably from 0.1 to 10. As the above branched-chain amino acid(s), either leucine or isoleucine alone may be contained. The present invention is suitably used as an infusion formulation, an oral formulation or a food or drink.
    Type: Grant
    Filed: May 27, 2014
    Date of Patent: July 4, 2017
    Assignee: OTSUKA PHARMACEUTICAL FACTORY, INC.
    Inventors: Masako Doi, Masuhiro Nishimura, Nozomi Tamura
  • Patent number: 9682025
    Abstract: The invention relates to the cosmetic use, by oral administration, of a combination of active agents including at least petroselinic acid and at least one active agent selected from among taurine, arginine, cysteine, zinc, a salt thereof, and lycopene, for improving the quality of nails, specifically the microvascularization of the nails, in particular in pre-hypertensive individuals.
    Type: Grant
    Filed: May 6, 2014
    Date of Patent: June 20, 2017
    Assignee: NUTRICOS TECHNOLOGIES
    Inventors: Yann Mahe, Carole Bru, Nathalie Piccardi, Audrey Gueniche
  • Patent number: 9675535
    Abstract: Disclosed herein is an antibacterial cleansing composition. The cleansing composition is free of triclosan and comprises lactic acid/lactate, at least one C2 to C3 alcohol, and glutamate diacetate. Lactic acid/lactate is present in the composition in an amount of about 5 weight percent (wt %) to about 15 wt %, based on the total weight of the composition. The C2 to C3 alcohol is present in an amount of about 1 wt % to about 20 wt %, based on the total weight of the composition. Glutamate diacetate is present in an amount of about 0.05 wt % to about 5 wt %. The pH of the composition is about 4 to about 5. The triclosan-free cleansing composition according to the invention has superior antibacterial activity that surpasses comparable triclosan-free formulations that do not contain glutamate diacetate.
    Type: Grant
    Filed: September 22, 2014
    Date of Patent: June 13, 2017
    Assignee: RUBBERMAID COMMERCIAL PRODUCTS/US
    Inventors: Yvan Vermeulen, Nirali Patel, John Van Cassel
  • Patent number: 9642390
    Abstract: The invention relates to a nutritional composition comprising (a) at least 18 en % of proteinaceous matter, said proteinaceous matter comprising whey; (b) at least 12 wt % of leucine, based on total proteinaceous matter; and (c) a lipid fraction comprising at least a ?-3 polyunsaturated fatty acid selected from the group of eicosapentaenoic acid, docosahexaenoic acid, eicosatetraenoic acid and docosapentaenoic acid for improving the muscle function in a mammal, for improving daily activity, for improving physical performance, for providing a better prognosis in terms of extended life-expectancy, for improving compliance to an anti-cancer therapy or for improving a quality of life.
    Type: Grant
    Filed: December 29, 2010
    Date of Patent: May 9, 2017
    Assignee: N.V. Nutricia
    Inventors: Klaske van Norren, Adrianus Lambertus Bertholdus van Helvoort, Joyce Faber, Robert Johan Joseph Hageman, Arjan Paul Vos
  • Patent number: 9623150
    Abstract: An injectable hydrogel, includes, in weight, in a physiologically acceptable carrier fluid: 0.01 to 5% of glycerol and 0.1 to 5% of cross-linked hyaluronic acid, or one of the salts thereof; characterized in that the hyaluronic acid or one of the salts thereof is cross-linked by the formation of covalent bonds using bifunctional or polyfunctional molecules, the injectable hydrogel being sterilized in moist heat and having viscoelastic properties such that Tan ? at a frequency of 1 Hz is less than or equal to 1.10. A method for producing the hydrogel, to a kit containing the hydrogel, as well as to the use thereof in dermatology are also described.
    Type: Grant
    Filed: May 14, 2010
    Date of Patent: April 18, 2017
    Assignee: ANTEIS S.A.
    Inventors: Samuel Gavard Molliard, Cyrille Vinchon
  • Patent number: 9499582
    Abstract: Compositions and methods utilizing thiol-containing short peptides having the sequence Cys-Lys-Met-Cys (SEQ ID NO: 1) and optionally N- and C-terminal modifications are described, for increasing carnitine level in muscle tissues, and treating or preventing diseases or disorders affecting muscle tissue.
    Type: Grant
    Filed: January 23, 2015
    Date of Patent: November 22, 2016
    Assignee: GENESISTEC LTD.
    Inventor: Josef Mograbi
  • Patent number: 9488664
    Abstract: It is to provide a tumor diagnostic agent and a tumor determination method enabling not only determination of the presence or absence of a tumor in a subject, but also determination of whether the tumor is a malignant tumor or a benign tumor, which can be used simply at low cost with reduced side effects and burden. 5-aminolevulinic acid (ALA) or its derivative, or a salt thereof is orally administered at a dose of 5 to 7 mg in terms of ALA per kg of body weight, and a urine sample 4 to 12 hours after the administration is collected. Porphyrins and creatinine in the urine sample are quantitated, and based on the value (nmol/gCre) obtained by dividing the amount of porphyrins by the amount of creatinine, a distinction among an individual without a tumor, an individual with a benign tumor, and an individual with a malignant tumor is determined. The presence or absence of a malignant tumor in a subject can be clearly determined by administering 1 to 3 mg of ALAs in terms of ALA per kg of body weight.
    Type: Grant
    Filed: January 15, 2013
    Date of Patent: November 8, 2016
    Assignee: SBI Pharmaceuticals Co., Ltd.
    Inventors: Tohru Tanaka, Kiwamu Takahashi, Motowo Nakajima, Fuminori Abe, Masahiro Ishizuka, Urara Ota